Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1340944

Cover Image

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1340944

Infection Control Surveillance Solutions Market - Global Outlook & Forecast 2023-2028

PUBLISHED:
PAGES: 313 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4200
PDF (5 User License)
USD 4999
PDF (Corporate User License)
USD 5999

Add to Cart

The global infection control surveillance solutions market is expected to grow at a CAGR of 13.47% from 2022 to 2028.

MARKET TRENDS & DRIVERS

Growing Transformation in Hospital Safety

Growing transformation in hospital safety driving infection control surveillance solutions market is a trend in which hospitals seek to improve patient safety and reduce patient infection levels through improved surveillance solutions. This transformation began in the late 2000s with the development of various electronic medical record systems used to capture patient data more efficiently and accurately. Now, hospitals invest in more sophisticated solutions to help detect or predict infections, use evidence-based protocols to implement best practices, and track outcomes over time. These solutions are powered by data analytics, AI, ML, and predictive modeling, enabling hospitals to better and more accurately detect and mitigate infection risks. In addition to improving patient safety, these solutions can help hospitals reduce costs, improve operational efficiency, and optimize quality of care.

Advancements in Cloud-based and AI-Integrated Software for Infection Surveillance and Control

Cloud-based and AI-integrated infection surveillance and control software is an incredibly important technology that enables public health organizations to detect and respond to infections quickly and effectively. Over the years, advancements in cloud-based and AI-integrated software have greatly improved the efficacy and efficiency of infection surveillance and control. By leveraging cloud-based solutions, public health organizations can store and manage large amounts of data efficiently and securely. In addition, they can access the data in real-time, allowing for more responsive action in the face of outbreaks. Another significant advancement in cloud-based and AI-integrated infection surveillance and control software is the integration of machine learning algorithms. Machine learning algorithms enable public health organizations to generate more detailed insights from the data, enabling them to understand the underlying infection patterns better and respond accordingly.

Growing Government Initiatives & Investment in IPC Programs Across Healthcare Settings

Infection surveillance solutions are used in healthcare settings to enable healthcare professionals to predict and prevent the spread of infectious diseases by detecting cases early, evaluating the effectiveness of interventions, and identifying tools that can be used to reduce the risk of transmission. Governments across the globe are introducing new policies and regulations that focus on developing long-term prevention programs and educating healthcare providers about the best practices for infection prevention and control. Aside from the need to maintain statistical records for the public, many governments also offer to fund healthcare centers and organizations to install more advanced software for infection surveillance. These initiatives allow organizations across healthcare facilities of different sizes to utilize state-of-the-art tools to prevent infections more efficiently, boosting the growth of the infection control surveillance solutions market.

SEGMENTATION INSIGHTS

INSIGHTS BY SOLUTION TYPE

The software solution type segment dominated the global infection control surveillance solutions market 2022. Infection control surveillance solutions have become increasingly important tools for healthcare providers and organizations in recent years. These solutions are designed to track and prevent the spread of infection in healthcare settings and can range from simple protocols to complex software and hardware systems. On-premises infection control surveillance solutions provide healthcare providers with a comprehensive suite of infection control tools while offering the benefits of a secure, offline environment. Further, hardware-based solutions are the core of effective on-premises infection control surveillance solutions. Secure databases allow organizations to track patient data, such as infections and immunizations, in one secure and centralized location.

Segmentation by Solution Type

  • Software
  • Services

INSIGHTS BY INFECTION TYPE

The global infection control surveillance solutions market by infection type as bloodstream infection (BSI), urinary tract infection (UTI), pneumonia (HAP & VAP), surgical site infection (SSI), and others. The bloodstream infection (BSI) segment accounted for the largest market share, accounting for over 33% in 2022. Bloodstream infections, or bacteremia, are serious and potentially life-threatening health conditions caused by bacteria entering the bloodstream. Infectious disease surveillance is a primary infection control and surveillance solution to prevent and manage bloodstream infections. This monitoring system allows for the early detection of infection and the identification of any individual experiencing septicemia. To do this, healthcare providers must collect data regarding any patient they believe may be at risk of developing a bloodstream infection. This data includes demographic information such as age and gender and any risk factor the patient may have, such as a chronic medical condition.

Segmentation by Infection Type

  • Bloodstream Infection (BSI)
  • Urinary Tract Infection (UTI)
  • Pneumonia (HAP & VAP)
  • Surgical Site Infection (SSI)
  • Others

INSIGHTS BY END-USER

The hospital end-user segment accounted for the largest global infection control surveillance solutions market share in 2022. Hospitals are the major sources of HAIs, and many hospitalized patients acquire pathogenic and non-pathogenic infectious during their stay. Most hospitals report CLABSI, CAUTI, SSIs, and other infections during surgical procedures and prolonged stays in ICUs. Surgical procedures include the use of invasive devices, implantation, and prosthesis. The hospital segment is dominating the global market and is witnessing steady growth in the forecasted period as hospitals & clinics are the first point of care source to get tested and treated for any disease than other healthcare settings. Infection control surveillance solutions are essential for hospitals to maintain cleanliness, compliance, and safety standards. Infection control surveillance solutions provide real-time data to give healthcare providers insight into existing and potential infection challenges and guide them in making the best decisions for their patients.

Segmentation by End-user

  • Hospitals
  • Outpatient Facilities
  • Long-term Care Facilities

GEOGRAPHICAL ANALYSIS

North America holds the largest global infection control surveillance solutions market share, accounting for over 34% in 2022. The large share can be attributed to the region's highly developed healthcare system and the high availability of government funds for research activities. Additionally, the region is witnessing strong investments in various aspects of the healthcare industry, including diagnosis and infection control, driving the market's growth.

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

VENDOR LANDSCAPE

The competitive scenario in the global infection control surveillance solutions market is currently intensifying due to the rapidly changing technological environment. This could significantly impact vendors as customers expect continual innovations and advancements for better prevention processes. The present situation is compelling vendors to alter and redefine their products following the introduction of defined legislation to achieve a strong market presence. The market is moderately fragmented, with many international players providing various infection control surveillance solutions. The infection control surveillance solutions market is dominating, especially in the U.S., owing to many major and prominent vendors in the region.

Key Company Profiles

  • BD
  • Epic Systems
  • Oracle
  • Premier
  • VigiLanz
  • Wolters Kluwer

Other Prominent Vendors

  • Baxter
  • CenTrak
  • Clinisys
  • Harris Healthcare
  • Medexter Healthcare
  • PointClickCare
  • Spacelabs Healthcare
  • Vecna Technologies
  • Ecolab
  • VIZZIA Technologies

KEY QUESTIONS ANSWERED:

1. How big is the infection control surveillance solutions market?

2. What is the projected growth rate of the global infection control surveillance solutions market?

3. Who are the key players in the global infection control surveillance solutions market?

4. What are the rising trends in the infection control surveillance solutions market?

5. Which region holds the most significant global infection control surveillance solutions market share?

Product Code: ARZ230707

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY SOLUTION TYPE
    • 4.3.2 MARKET SEGMENTATION BY INFECTION TYPE
    • 4.3.3 MARKET SEGMENTATION BY END-USER
    • 4.3.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

  • 6.1 OVERVIEW
    • 6.1.1 GEOGRAPHY INSIGHTS
    • 6.1.2 SOLUTION TYPE INSIGHTS
    • 6.1.3 INFECTION TYPE INSIGHTS
    • 6.1.4 END-USER INSIGHTS

7 MARKET AT A GLANCE

8 INTRODUCTION

  • 8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

  • 9.1 GROWTH IN ADOPTION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS (ASP)
  • 9.2 CLINICAL SURVEILLANCE IS NEXT STEP IN VALUE-BASED CARE
  • 9.3 ADVANCES IN CLOUD-BASED AND AI-INTEGRATED SOFTWARE FOR INFECTION SURVEILLANCE AND CONTROL

10 MARKET GROWTH ENABLERS

  • 10.1 GROWING PREVALENCE OF HOSPITAL-ACQUIRED INFECTIONS (HAI)
  • 10.2 INCREASING NUMBER OF SURGERIES
  • 10.3 GROWING TRANSFORMATION IN HOSPITAL SAFETY
  • 10.4 GROWING GOVERNMENT INITIATIVES & INVESTMENT IN IPC PROGRAMS ACROSS HEALTHCARE SETTINGS

11 MARKET RESTRAINTS

  • 11.1 HIGH DEPLOYMENT COST OF INFECTION CONTROL SURVEILLANCE SOLUTIONS
  • 11.2 DATA SECURITY CONCERNS
  • 11.3 RELUCTANCE TO ADOPT ADVANCED HEALTHCARE IT SOLUTIONS

12 MARKET LANDSCAPE

  • 12.1 MARKET OVERVIEW
  • 12.2 MARKET SIZE & FORECAST
  • 12.3 MARKET OPPORTUNITY
    • 12.3.1 MARKET BY GEOGRAPHY
    • 12.3.2 MARKET BY SOLUTION TYPE
    • 12.3.3 MARKET BY INFECTION TYPE
    • 12.3.4 MARKET BY END-USER
  • 12.4 FIVE FORCES ANALYSIS
    • 12.4.1 THREAT OF NEW ENTRANTS
    • 12.4.2 BARGAINING POWER OF SUPPLIERS
    • 12.4.3 BARGAINING POWER OF BUYERS
    • 12.4.4 THREAT OF SUBSTITUTES
    • 12.4.5 COMPETITIVE RIVALRY

13 SOLUTION TYPE

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 SOFTWARE
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 MARKET BY GEOGRAPHY
  • 13.4 SERVICES
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 MARKET BY GEOGRAPHY

14 INFECTION TYPE

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 BLOOD STREAM INFECTION (BSI)
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 MARKET BY GEOGRAPHY
  • 14.4 URINARY TRACT INFECTION (UTI)
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 MARKET BY GEOGRAPHY
  • 14.5 PNEUMONIA (HAP & VAP)
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
    • 14.5.3 MARKET BY GEOGRAPHY
  • 14.6 SURGICAL SITE INFECTION (SSI)
    • 14.6.1 MARKET OVERVIEW
    • 14.6.2 MARKET SIZE & FORECAST
    • 14.6.3 MARKET BY GEOGRAPHY
  • 14.7 OTHERS
    • 14.7.1 MARKET OVERVIEW
    • 14.7.2 MARKET SIZE & FORECAST
    • 14.7.3 MARKET BY GEOGRAPHY

15 END-USER

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 HOSPITALS
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 MARKET BY GEOGRAPHY
  • 15.4 OUTPATIENT FACILITIES
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 MARKET BY GEOGRAPHY
  • 15.5 LONG-TERM CARE FACILITIES
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 MARKET BY GEOGRAPHY

16 GEOGRAPHY

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
    • 17.2.1 MARKET BY SOLUTION TYPE
    • 17.2.2 MARKET BY INFECTION TYPE
    • 17.2.3 MARKET BY END-USER
  • 17.3 KEY COUNTRIES
    • 17.3.1 US: MARKET SIZE & FORECAST
    • 17.3.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
    • 18.2.1 MARKET BY SOLUTION TYPE
    • 18.2.2 MARKET BY INFECTION TYPE
    • 18.2.3 MARKET BY END-USER
  • 18.3 KEY COUNTRIES
    • 18.3.1 GERMANY: MARKET SIZE & FORECAST
    • 18.3.2 UK: MARKET SIZE & FORECAST
    • 18.3.3 FRANCE: MARKET SIZE & FORECAST
    • 18.3.4 ITALY: MARKET SIZE & FORECAST
    • 18.3.5 SPAIN: MARKET SIZE & FORECAST

19 APAC

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 MARKET BY SOLUTION TYPE
    • 19.2.2 MARKET BY INFECTION TYPE
    • 19.2.3 MARKET BY END-USER
  • 19.3 KEY COUNTRIES
    • 19.3.1 CHINA: MARKET SIZE & FORECAST
    • 19.3.2 JAPAN: MARKET SIZE & FORECAST
    • 19.3.3 INDIA: MARKET SIZE & FORECAST
    • 19.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
    • 19.3.5 AUSTRALIA: MARKET SIZE & FORECAST

20 LATIN AMERICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 MARKET BY SOLUTION TYPE
    • 20.2.2 MARKET BY INFECTION TYPE
    • 20.2.3 MARKET BY END-USER
  • 20.3 KEY COUNTRIES
    • 20.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 20.3.2 MEXICO: MARKET SIZE & FORECAST
    • 20.3.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
    • 21.2.1 MARKET BY SOLUTION TYPE
    • 21.2.2 MARKET BY INFECTION TYPE
    • 21.2.3 MARKET BY END-USER
  • 21.3 KEY COUNTRIES
    • 21.3.1 TURKEY: MARKET SIZE & FORECAST
    • 21.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
    • 21.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

  • 22.1 COMPETITION OVERVIEW
  • 22.2 MARKET SHARE ANALYSIS
    • 22.2.1 BD
    • 22.2.2 EPIC SYSTEMS
    • 22.2.3 ORACLE
    • 22.2.4 PREMIER
    • 22.2.5 VIGILANZ
    • 22.2.6 WOLTERS KLUWER

23 KEY COMPANY PROFILES

  • 23.1 BD
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 PRODUCT OFFERINGS
    • 23.1.3 KEY STRATEGIES
    • 23.1.4 KEY STRENGTHS
    • 23.1.5 KEY OPPORTUNITIES
  • 23.2 EPIC SYSTEMS
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 PRODUCT OFFERINGS
    • 23.2.3 KEY STRATEGIES
    • 23.2.4 KEY STRENGTHS
    • 23.2.5 KEY OPPORTUNITIES
  • 23.3 ORACLE
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 PRODUCT OFFERINGS
    • 23.3.3 KEY STRATEGIES
    • 23.3.4 KEY STRENGTHS
    • 23.3.5 KEY OPPORTUNITIES
  • 23.4 PREMIER
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 PRODUCT OFFERINGS
    • 23.4.3 KEY STRATEGIES
    • 23.4.4 KEY STRENGTHS
    • 23.4.5 KEY OPPORTUNITIES
  • 23.5 VIGILANZ
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 PRODUCT OFFERINGS
    • 23.5.3 KEY STRATEGIES
    • 23.5.4 KEY STRENGTHS
    • 23.5.5 KEY OPPORTUNITIES
  • 23.6 WOLTERS KLUWER
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 PRODUCT OFFERINGS
    • 23.6.3 KEY STRATEGIES
    • 23.6.4 KEY STRENGTHS
    • 23.6.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

  • 24.1 BAXTER
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 PRODUCT OFFERINGS
  • 24.2 CENTRAK
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 PRODUCT OFFERINGS
  • 24.3 CLINISYS
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 PRODUCT OFFERINGS
  • 24.4 HARRIS HEALTHCARE
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 PRODUCT OFFERINGS
  • 24.5 MEDEXTER HEALTHCARE
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 PRODUCT OFFERINGS
  • 24.6 POINTCLICKCARE
    • 24.6.1 BUSINESS OVERVIEW
    • 24.6.2 PRODUCT OFFERINGS
  • 24.7 SPACELABS HEALTHCARE
    • 24.7.1 BUSINESS OVERVIEW
    • 24.7.2 PRODUCT OFFERINGS
  • 24.8 VECNA TECHNOLOGIES
    • 24.8.1 BUSINESS OVERVIEW
    • 24.8.2 PRODUCT OFFERINGS
  • 24.9 ECOLAB
    • 24.9.1 BUSINESS OVERVIEW
    • 24.9.2 PRODUCT OFFERINGS
  • 24.10 VIZZIA TECHNOLOGIES
    • 24.10.1 BUSINESS OVERVIEW
    • 24.10.2 PRODUCT OFFERINGS

25 REPORT SUMMARY

  • 25.1 KEY TAKEAWAYS
  • 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

  • 26.1 MARKET BY SOLUTION TYPE
    • 26.1.1 NORTH AMERICA
    • 26.1.2 EUROPE
    • 26.1.3 APAC
    • 26.1.4 LATIN AMERICA
    • 26.1.5 MIDDLE EAST & AFRICA
  • 26.2 MARKET BY INFECTION TYPE
    • 26.2.1 NORTH AMERICA
    • 26.2.2 EUROPE
    • 26.2.3 APAC
    • 26.2.4 LATIN AMERICA
    • 26.2.5 MIDDLE EAST & AFRICA
  • 26.3 MARKET BY END-USER
    • 26.3.1 NORTH AMERICA
    • 26.3.2 EUROPE
    • 26.3.3 APAC
    • 26.3.4 LATIN AMERICA
    • 26.3.5 MIDDLE EAST & AFRICA
  • 26.4 MARKET BY GEOGRAPHY
    • 26.4.1 SOFTWARE
    • 26.4.2 SERVICES
    • 26.4.3 BLOOD STREAM INFECTION (BSI)
    • 26.4.4 URINARY TRACT INFECTION (UTI)
    • 26.4.5 PNEUMONIA (HAP & VAP)
    • 26.4.6 SURGICAL SITE INFECTION (SSI)
    • 26.4.7 OTHERS
    • 26.4.8 HOSPITALS
    • 26.4.9 OUTPATIENT FACILITIES
    • 26.4.10 LONG-TERM CARE FACILITIES

27 APPENDIX

  • 27.1 ABBREVIATIONS
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!